Dyne Therapeutics expands debt facility to $400 million
Dyne Therapeutics amended its senior secured term loan facility with Hercules Capital, increasing total capacity to $400 million. The amendment includes $50 million in immediate funding and $125 million in additional borrowing capacity. The company has borrowed $200 million to date and retains access to $200 million for future funding.
*this image is generated using AI for illustrative purposes only.
Dyne Therapeutics has expanded its debt financing capacity to $400 million through an amendment to its senior secured term loan facility with Hercules Capital. The agreement provides an additional $125 million in borrowing capacity, strengthening the company's balance sheet as it advances clinical programs for Duchenne muscular dystrophy and myotonic dystrophy type 1. The increased capital offers strategic flexibility as Dyne prepares for potential U.S. product launches in the next two years.
Under the terms of the amendment, $50 million was funded immediately upon execution. The facility also includes an additional term loan tranche of $50 million, available at Dyne's option subject to achieving specific milestones. Furthermore, the final term loan tranche was increased by $25 million, providing access to an additional $75 million upon request and at Hercules Capital's discretion.
Debt Facility Structure
The amendment modifies the existing loan structure, increasing the total available capital while maintaining secured status. The facility is non-dilutive, allowing Dyne to fund operations without issuing additional equity.
| Component | Amount | Status |
|---|---|---|
| Immediate funding | $50 million | Funded at closing |
| Optional milestone tranche | $50 million | Subject to milestones |
| Final term loan tranche increase | $75 million | At lender's discretion |
| Total additional capacity | $125 million | — |
| Total facility capacity | $400 million | — |
With the $50 million funded at closing, Dyne has drawn an aggregate of $200 million in loan proceeds across three tranches. The company maintains access to the remaining $200 million in potential future funding under the facility.
Erick Lucera, chief financial officer of Dyne, stated that the additional capital enhances financial flexibility for upcoming clinical and regulatory objectives. R. Bryan Jadot, Senior Managing Director at Hercules Capital, affirmed the lender's increased commitment reflects confidence in Dyne's programs.
What specific clinical milestones must Dyne achieve to unlock the optional $50 million tranche?
How will Dyne prioritize the allocation of the immediate $50 million funding across its Duchenne and myotonic dystrophy programs?
What are the anticipated cash burn rates following the U.S. product launches, and will current funding suffice through to commercialization?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
